Hematology biotech companies

The 4 hematology companies we cover, with cash and runway from their latest SEC filings, trial milestones from ClinicalTrials.gov, and FDA decisions from their own 8-Ks. Companies are tagged by the areas their pipelines target.

Companies

CompanyMost advanced programCash & investmentsRunwayProfile
CRSPCRISPR TherapeuticsCasgevy (exagamglogene autotemcel) · Sickle cell disease and transfusion-dependent beta-thalassemiaApproved$2.36B2026-06-30~74 momaintained
KROSKeros TherapeuticsKER-065 · Duchenne Muscular DystrophyPhase 2$258M2026-06-30~65 momaintained
BEAMBeam TherapeuticsBEAM-101 · sickle cell diseasePhase 1no filing parsed—archived
INCYIncyteJakafi · myelofibrosis and graft-versus-host diseaseApprovedno filing parsed—archived

Runway is cash divided by quarterly operating burn and is not shown for companies funded by their own revenue. Figures and their dates are on each company page, linked to the filing.

Upcoming trial milestones

  • 2026-12 · BEAM · BEAM-201 T-ALL: BEAM-201 in Relapsed/refractory T-ALL or T-LL — primary completion ClinicalTrials.gov
  • 2027-09-28 · INCY · AXemplify-357: Axatilimab in Chronic graft-versus-host disease, first line — primary completion ClinicalTrials.gov
  • 2027-12-30 · BEAM · BEAM-301 GSDIa: BEAM-301 in Glycogen storage disease type Ia — primary completion ClinicalTrials.gov
  • 2028-05 · BEAM · BEAM-302 AATD: BEAM-302 in Alpha-1 antitrypsin deficiency — primary completion ClinicalTrials.gov
  • 2028-11-15 · INCY · INCB123667 ovarian: INCB123667 in Platinum-resistant ovarian cancer, cyclin E1 overexpression — primary completion ClinicalTrials.gov
  • 2029-06-15 · INCY · EXCALIBUR-ET2: INCA033989 in CALR-mutant essential thrombocythemia — primary completion ClinicalTrials.gov

A registry milestone is the date data collection is scheduled to end, not the date results are released.

FDA decisions

None of these companies has an FDA decision on our PDUFA calendar, which lists only dates a company has stated in a filing.

Educational information, not investment advice. See where each field comes from.